Breaking News Instant updates and real-time market news.

SRRA

Sierra Oncology

$2.93

-0.05 (-1.68%)

, JNJ

Johnson & Johnson

$132.07

0.89 (0.68%)

07:14
02/27/18
02/27
07:14
02/27/18
07:14

Sierra Oncology, Janssen sign sign supply agreement for prostate cancer study

Sierra Oncology (SRRA) announced the signing of a clinical supply agreement with Janssen Research & Development (JNJ) for access to Tesaro's (TSRO) ZEJULA, an orally administered poly polymerase inhibitor undergoing clinical development by Janssen for patients with prostate cancer. Sierra intends to evaluate its Chk1 inhibitor, SRA737, in combination with niraparib in patients with metastatic castration-resistant prostate cancer. The scientific rationale for the combination was supported by translational research conducted at The Institute of Cancer Research, London. Sierra plans to conduct an open-label, multicenter Phase 1b/2 dose-ranging study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SRA737 in combination with niraparib in patients with mCRPC. The study is intended to determine the maximum tolerated dose and schedule of SRA737 in combination with niraparib and to propose a recommended Phase 2 dose and schedule of the combination. Data will be analyzed to examine specific hypotheses regarding the relationship between clinical response and alterations in genes regulating cell cycle progression and DNA damage response. Janssen will provide Sierra with niraparib, while Sierra will conduct and control the study, which is anticipated to commence in the fourth quarter of 2018. Preclinical studies evaluating the combination of SRA737 and niraparib are ongoing.

SRRA

Sierra Oncology

$2.93

-0.05 (-1.68%)

JNJ

Johnson & Johnson

$132.07

0.89 (0.68%)

TSRO

Tesaro

$59.77

-0.97 (-1.60%)

  • 27

    Feb

  • 02

    Mar

  • 08

    Mar

SRRA Sierra Oncology
$2.93

-0.05 (-1.68%)

10/23/17
JEFF
10/23/17
UPGRADE
Target $4
JEFF
Buy
Sierra Oncology upgraded to Buy from Hold at Jefferies
Jefferies analyst Maury Raycroft upgraded Sierra Oncology to Buy and raised his price target for the shares to $4.00 from $1.50. The company is "rapidly advancing" SRA737 through dose-escalation in two clinical studies and the program is "under-the-radar," Raycroft tells investors in a research note. He believes Sierra's clinical strategy is "differentiated and innovative" and recommends buying the shares ahead of the Q1 of 2018 data.
03/10/17
RHCO
03/10/17
UPGRADE
Target $4
RHCO
Buy
Sierra Oncology upgraded to Buy from Hold at SunTrust
SunTrust analyst Yatin Suneja upgraded Sierra Oncology to Buy with a $4 price target. The analyst believes lead candidate SRA737 has produced favorable preclinical data, in-line with other clinical candidates targeting similar pathways, and may have wide applicability across multiple tumor types.
03/02/17
03/02/17
NO CHANGE

Sierra Oncology reports Q4 EPS (30c), consensus (29c)
JNJ Johnson & Johnson
$132.07

0.89 (0.68%)

01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
TSRO Tesaro
$59.77

-0.97 (-1.60%)

02/22/18
02/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Palo Alto Networks (PANW) upgraded to Buy from Neutral at Cleveland Research with the firm saying it's channel partner checks indicate favorable revenue/billings growth in the low-20% range, versus high teens previously, and the product refresh could be a source of upside with increased hardware growth. 2. Verisk Analytics (VRSK) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Steinerman saying he believes sustainable high-single-digit organic revenue growth is "back in sight" following last night's "strong" fourth quarter results. 3. Tesaro (TSRO) upgraded to Outperform from In Line at Evercore ISI with analyst Steven Breazzano saying he believes the stocks' valuations are now attractive on a long-term basis following their pullbacks. 4. Clovis (CLVS) was upgraded to Outperform from In Line at Evercore ISI and to Outperform from Sector Perform at RBC Capital. 5. Wolverine World Wide (WWW) upgraded to Buy from Neutral at DA Davidson with analyst Andrew Burns saying the company is positioned for accelerating growth following a multi-year restructuring. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/18
02/22/18
UPGRADE

Outperform
Evercore ISI upgrades Clovis, Tesaro with PARP potential 'too big to ignore'
As previously reported, Evercore ISI analyst Steven Breazzano upgraded Clovis (CLVS) and Tesaro (TSRO), both to Outperform from In Line, as he believes the stocks' valuations are now attractive on a long-term basis following their pullbacks. He views adoption of the PARP class so far as robust, particularly in ovarian cancer, and sees further upside as PARPs move up into earlier lines of therapy, combination studies, and new indications. However, Breazzano lowered his price target on Clovis shares to $72 from $73 and decreased his target on Tesaro to $88 from $121.
02/22/18
EVER
02/22/18
UPGRADE
EVER
Outperform
Tesaro upgraded to Outperform from In Line at Evercore ISI
01/18/18
FBCO
01/18/18
NO CHANGE
Target $150
FBCO
Outperform
Tesaro price target lowered to $150 from $190 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Tesaro to $150 from $190 to include lower than forecasted Zejula or Varubi sales or clinical setbacks. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CLF

Cleveland-Cliffs

$9.95

1.12 (12.68%)

05:38
07/23/18
07/23
05:38
07/23/18
05:38
Upgrade
Cleveland-Cliffs rating change  »

Cleveland-Cliffs upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

BrightView

$21.95

0.14 (0.64%)

05:29
07/23/18
07/23
05:29
07/23/18
05:29
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMO

Sangamo

$15.10

0.025 (0.17%)

05:28
07/23/18
07/23
05:28
07/23/18
05:28
Hot Stocks
Sangamo to acquire TxCell for EUR 2.58 per share in cash »

Sangamo Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

BrightView

$21.95

0.14 (0.64%)

05:27
07/23/18
07/23
05:27
07/23/18
05:27
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCM

Hutchison China MediTech

$33.92

0.89 (2.69%)

05:25
07/23/18
07/23
05:25
07/23/18
05:25
Hot Stocks
Chi-Med initiates Phase Ib/II proof-of-concept study of sulfatib »

Hutchison China MediTech,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

05:23
07/23/18
07/23
05:23
07/23/18
05:23
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:22
07/23/18
07/23
05:22
07/23/18
05:22
Hot Stocks
Roche receives CE Mark for Accu-Chek Solo micropump system »

Roche announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

PZZA

Papa John's

$51.61

0.62 (1.22%)

05:22
07/23/18
07/23
05:22
07/23/18
05:22
Hot Stocks
Papa John's adopts limited duration stockholder rights plan »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

05:21
07/23/18
07/23
05:21
07/23/18
05:21
General news
Trump tells Iranian President to 'never, ever threaten' U.S. again »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$26.27

-0.44 (-1.65%)

05:19
07/23/18
07/23
05:19
07/23/18
05:19
Initiation
Neuronetics initiated  »

Neuronetics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$51.61

0.62 (1.22%)

05:17
07/23/18
07/23
05:17
07/23/18
05:17
Downgrade
Papa John's rating change  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$166.47

-0.47 (-0.28%)

05:16
07/23/18
07/23
05:16
07/23/18
05:16
Hot Stocks
Accenture forms strategic alliance with Ripjar, terms not disclosed »

Accenture has formed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

BV

BrightView

$21.95

0.14 (0.64%)

05:12
07/23/18
07/23
05:12
07/23/18
05:12
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCDA

Tricida

$29.50

-0.42 (-1.40%)

05:10
07/23/18
07/23
05:10
07/23/18
05:10
Initiation
Tricida initiated  »

Tricida initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

BrightView

$21.95

0.14 (0.64%)

05:08
07/23/18
07/23
05:08
07/23/18
05:08
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSM

Insmed

$24.98

-0.12 (-0.48%)

05:07
07/23/18
07/23
05:07
07/23/18
05:07
Initiation
Insmed initiated  »

Insmed initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 28

    Sep

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

05:04
07/23/18
07/23
05:04
07/23/18
05:04
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

05:01
07/23/18
07/23
05:01
07/23/18
05:01
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$80.64

-0.56 (-0.69%)

04:58
07/23/18
07/23
04:58
07/23/18
04:58
Upgrade
Duke Energy rating change  »

Duke Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

STI

SunTrust

$70.86

1.855 (2.69%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Upgrade
SunTrust rating change  »

SunTrust upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$6.87

-0.08 (-1.15%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
Miragen Therapeutics management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
RBC Capital commodity strategist to hold a dinner meeting »

Commodity Strategist…

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

SAR

Saratoga Investment

$24.59

0.08 (0.33%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
Saratoga Investment management to meet with Compass Point »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.